文献速递胸部肿瘤放疗

局部晚期非小细胞肺癌淋巴结转移灶减量减边放疗的安全性与疗效

Safety and efficacy of reduced dose and margins to involved lymph node metastases in locally advanced NSCLC patients.
PubMed 文献 · Radiother Oncol · 2019-08-17

该观察性研究纳入308例局部晚期非小细胞肺癌患者,比较淋巴结引流区减量(60 Gy EQD210)联合PTV边距缩小2-3 mm与标准70 Gy方案的毒性及疗效。减量组急性3级吞咽困难和3级肺毒性显著降低,区域失败率无差异,总生存期显著延长。

要点

  • 淋巴结减量至60 Gy并缩小PTV边距未增加区域失败率。
  • 减量组急性3级吞咽困难和肺毒性显著低于标准组。
  • 减量组中位总生存期显著优于标准组。

核心结论

  • 局部晚期非小细胞肺癌放疗中,将受累淋巴结剂量从70 Gy降至60 Gy并缩小PTV边距2-3 mm,未增加区域失败,且急性毒性显著降低、总生存期改善。

研究设计与样本

  • 观察性研究纳入308例局部晚期非小细胞肺癌患者,参考组170例接受淋巴结70 Gy(EQD210),减量组138例接受淋巴结60 Gy(EQD210)并缩小PTV边距2-3 mm。

主要发现

  • 急性3级吞咽困难从12.9%降至3.6%,3级肺毒性从4.1%降至0%。
  • 区域失败率参考组5.9% vs 减量组4.3%(p=0.546),无显著差异。
  • 中位总生存期参考组26个月 vs 减量组35个月,校正混杂因素后减量组与OS的关联仍显著(HR 0.63 vs HR 0.70)。

关键数值与推荐

  • 原发肿瘤均接受大分割放疗24×2.75 Gy(70 Gy EQD210)。
  • 参考组淋巴结接受70 Gy(EQD210),减量组淋巴结接受24×2.42 Gy(生物等效60 Gy EQD210)。

临床怎么用

  • 对局部晚期非小细胞肺癌患者,可考虑将受累淋巴结剂量降至60 Gy并缩小PTV边距2-3 mm以减少严重吞咽困难和肺毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: (Chemo)Radiotherapy for locally advanced non-small lung cancer (LA-NSCLC) causes severe dysphagia due to the radiation dose to the mediastinal lymphadenopathy. Reducing the dose to the mediastinum and the margins to the planning target volume (PTV) might reduce severe toxicity rates. The results of both adaptations in LA-NSCLC patients receiving (chemo)radiotherapy were analysed. MATERIALS AND METHODS: 308 LA-NSCLC patients were included in an observational study. Both cohorts received hypofractionated RT (24 × 2.75 Gy) of 70 Gy (EQD210) to the primary tumour. The reference-cohort (N = 170) received the same dose of 70 Gy (EQD210) to the involved lymph nodes, while the reduction-cohort (N = 138) received 24 × 2.42 Gy, biologically equivalent to 60 Gy (EQD210). Furthermore, the patient-specific PTV-margins for both the primary tumour and lymph nodes were reduced by 2-3 mm in the reduction-cohort after implementing a carina based correction strategy. The effects on toxicity, regional failure and overall survival (OS) were assessed. RESULTS: The acute grade 3 (G3) dysphagia and G3 pulmonary toxicity decreased significantly from 12.9% to 3.6% and 4.1% versus 0%, respectively. The regional failures were comparable: 5.9% versus 4.3% (p = 0.546). The median OS was significantly different: 26 months (reference-cohort) versus 35 months (reduction-cohort). After correction for confounders, the association between the reduction-cohort and OS remained significant (HR 0.63 versus HR 0.70). CONCLUSION: A reduction in PTV-margins and dose from 70 Gy to 60 Gy to the involved lymph nodes in LA-NSCLC patients receiving (chemo)radiotherapy did not result in an increase in regional failures. Moreover, significantly lower acute toxicities and an improved OS were observed in the reduction-cohort.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. van Diessen JNA, Kwint M, Sonke JJ, et al. Safety and efficacy of reduced dose and margins to involved lymph node metastases in locally advanced NSCLC patients. Radiother Oncol. 2019. PMID: 31431389. doi:10.1016/j.radonc.2019.07.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。